Literature DB >> 19084425

Association of IL6 and IL10 with renal dysfunction and the use of haemofiltration during cardiopulmonary bypass.

Ghassan S Musleh1, Subir S Datta, Nizar N Yonan, Geir J Grotte, Brian A Prendergast, Ragheb I Hasan, Abdul K Deyrania.   

Abstract

OBJECTIVE: Assessment of the effects of haemofiltration during cardiopulmonary bypass (CPB) in coronary artery bypass grafting (CABG) on the renal function and correlation with interleukin 6 (IL6) and interleukin 10 (IL10) levels.
METHODS: Seventy-nine patients scheduled for elective CABG were prospectively randomised into two groups. Group A with a haemofilter attached to arterial line of the CPB circuit and group B without a haemofilter. The two groups were comparable in their symptoms, sex, and previous history of myocardial infarction, left ventricular function, cross-clamp time, bypass time and total grafting per patients. Blood urea and creatinine levels were measured the day before operation, 12h after operation and on the 3rd postoperative day. IL6 and IL10 were measured in blood samples collected 1h before surgery, on arrival to ITU and after 12h. IL6 and IL10 levels were measured using ELISA test.
RESULTS: High levels of IL6 (>100 pg/ml) postoperatively were associated with increased incidence of renal dysfunction (p<0.017). Additionally, high IL10 (>30 pg/ml) levels postoperatively were associated with increased incidence of renal dysfunction (p<0.014). There were no effects of the haemofilter on postoperative IL6 and IL10 levels. Use of haemofiltration during CPB was found not to be protective against renal dysfunction (p<0.071).
CONCLUSIONS: Haemofilter use during cardiopulmonary bypass does not have a protective effect on postoperative kidney function. Haemofilter has no effect on the level of IL6 and IL10.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19084425     DOI: 10.1016/j.ejcts.2008.10.010

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery.

Authors:  William R Zhang; Amit X Garg; Steven G Coca; Philip J Devereaux; John Eikelboom; Peter Kavsak; Eric McArthur; Heather Thiessen-Philbrook; Colleen Shortt; Michael Shlipak; Richard Whitlock; Chirag R Parikh
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

2.  Preoperative statin therapy in cardiac surgery is more effective in patients who display preoperative activation of the inflammatory system.

Authors:  José Martínez-Comendador; José Rubio Alvarez; Juan Sierra; Elvis Teijeira; Belén Adrio
Journal:  Tex Heart Inst J       Date:  2013

3.  The effect of conventional and mini-invasive cardiopulmonary bypass on neutrophil activation in patients undergoing coronary artery bypass grafting.

Authors:  Martina Kolackova; Jan Krejsek; Vladimir Svitek; Pavel Kunes; Jiri Mandak; Zdenka Holubcova; Vladimir Lonsky
Journal:  Mediators Inflamm       Date:  2012-02-19       Impact factor: 4.711

4.  IL-6 serum levels predict postoperative morbidity in gastric cancer patients.

Authors:  Antoni M Szczepanik; Lucyna Scislo; Thecla Scully; Elzbieta Walewska; Maciej Siedlar; Piotr Kolodziejczyk; Marzena Lenart; Magdalena Rutkowska; Aleksander Galas; Antoni Czupryna; Jan Kulig
Journal:  Gastric Cancer       Date:  2011-04-20       Impact factor: 7.370

5.  Acute coronary syndrome and acute kidney injury: role of inflammation in worsening renal function.

Authors:  Jorge Ortega-Hernández; Rashidi Springall; Fausto Sánchez-Muñoz; Julio-C Arana-Martinez; Héctor González-Pacheco; Rafael Bojalil
Journal:  BMC Cardiovasc Disord       Date:  2017-07-26       Impact factor: 2.298

6.  Ultrafiltration and cardiopulmonary bypass associated acute kidney injury: A systematic review and meta-analysis.

Authors:  Omneya A Kandil; Karam R Motawea; Edward Darling; Jeffrey B Riley; Jaffer Shah; Mohamed Abdalla Mohamed Elashhat; Bruce Searles; Hani Aiash
Journal:  Clin Cardiol       Date:  2021-11-27       Impact factor: 2.882

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.